Point72 Asset Management L.P. Makes New $1.92 Million Investment in Orchard Therapeutics PLC – (NASDAQ:ORTX)

Point72 Asset Management L.P. purchased a new stake in Orchard Therapeutics PLC – (NASDAQ:ORTX) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 161,200 shares of the company’s stock, valued at approximately $1,915,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Maven Securities LTD bought a new stake in shares of Orchard Therapeutics in the 2nd quarter valued at approximately $144,000. Athanor Capital LP acquired a new stake in Orchard Therapeutics during the second quarter worth about $200,000. D. E. Shaw & Co. Inc. bought a new stake in Orchard Therapeutics in the 2nd quarter valued at $236,000. Stanley Laman Group Ltd. bought a new stake in Orchard Therapeutics in the second quarter valued at about $256,000. Finally, Virtus ETF Advisers LLC bought a new stake in shares of Orchard Therapeutics in the 2nd quarter valued at approximately $256,000. Institutional investors own 69.25% of the company’s stock.

Orchard Therapeutics stock opened at $11.86 on Wednesday. The business’s fifty day moving average is $11.59 and its two-hundred day moving average is $13.70. The company has a debt-to-equity ratio of 0.07, a quick ratio of 8.88 and a current ratio of 8.88. The firm has a market cap of $1.10 billion, a P/E ratio of -1.16 and a beta of -1.18. Orchard Therapeutics PLC – has a 52 week low of $8.65 and a 52 week high of $21.64.

Orchard Therapeutics (NASDAQ:ORTX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.05. The business had revenue of $1.92 million during the quarter, compared to analyst estimates of $0.53 million. On average, equities research analysts predict that Orchard Therapeutics PLC – will post -1.83 earnings per share for the current year.

Several brokerages recently commented on ORTX. Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Orchard Therapeutics in a research note on Monday. Barclays began coverage on Orchard Therapeutics in a research note on Thursday, September 5th. They set an “overweight” rating and a $21.00 price objective for the company. Guggenheim started coverage on Orchard Therapeutics in a report on Tuesday, September 17th. They set a “buy” rating and a $31.00 price objective for the company. Oppenheimer initiated coverage on shares of Orchard Therapeutics in a research note on Thursday, August 29th. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Orchard Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 11th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $24.71.

Orchard Therapeutics Profile

Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.

Recommended Story: Commodities

Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics PLC – (NASDAQ:ORTX).

Institutional Ownership by Quarter for Orchard Therapeutics (NASDAQ:ORTX)

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.